The combined activity of STING agonist‐mediated immune stimulation and OVA antigen release promoted the expression of IFN‐β, TNF‐α, and chemokines CXCL9 and CXCL10.[100c] This resulted in the recruitment and activation of CD8+ T lymphocytes, effectively inhibiting tumor progression and prolonging survival in murine B16 F10‐OVA subcutaneousmelanoma models. This evidence concerns the gene STING1 and neoplasm.